Indivior-Supernus Merger Proxy Sets October 15 Vote; $1B Special Dividend and $650M Financing Detailed
INDV sits 55% above its 52-week low of $22.22.
Summary
Indivior and Supernus set October 15, 2026 for shareholder votes on their merger of equals, with Indivior issuing ~89.7M shares and paying a $1B Special Dividend funded by a $650M term loan.
Key Events · M&A and Partnerships · INDV
-
Shareholder Vote Set for October 15
Both Indivior and Supernus special meetings will be held virtually on October 15, 2026, with a record date of September 4, 2026. Indivior stockholders vote on the share issuance; Supernus stockholders vote on adopting the merger agreement.
-
89.7M Shares to Be Issued
Indivior expects to issue approximately 89,669,250 shares to Supernus stockholders at the fixed exchange ratio of 1.5401 Indivior shares per Supernus share, giving Supernus holders ~43.5% of the combined company.
-
$1B Special Dividend Funded by $650M Loan
Indivior will pay a $1 billion Special Dividend to its stockholders, funded by a $650 million senior secured term loan from Citibank plus available cash. An Alternative Dividend Scenario provides $500 million cash plus $529.5 million in deferred payment rights if financing is unavailable.
-
HSR Waiting Period Expires September 21
The Hart-Scott-Rodino antitrust waiting period is set to expire at 11:59 p.m. Eastern Time on September 21, 2026, unless extended, clearing a key regulatory condition for closing.
Analysis · INDV · Life Sciences
This definitive proxy statement/prospectus advances the Indivior-Supernus merger of equals toward completion by setting the shareholder vote for October 15, 2026, with a record date of September 4, 2026. It quantifies the share issuance at approximately 89.7 million Indivior shares, which would give Supernus stockholders roughly 43.5% of the combined company. The filing also details the $1 billion Special Dividend to Indivior stockholders, funded in part by a new $650 million senior secured term loan from Citibank, with an Alternative Dividend Scenario of $500 million cash plus $529.5 million in deferred payment rights if financing falls through. The HSR waiting period expires September 21, 2026, clearing a key regulatory hurdle. Both boards unanimously recommend approval, and the merger is expected to close in Q4 2026.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.7% of the 1694 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDV was trading at $34.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $22.22 to $42.81. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.